Caris Life Sciences, Inc. (CAI) · Peers
Caris Life Sciences against the 24 other companies here in its SEC industry, Services-Medical Laboratories. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 25, highest first.
Measure by measure
| Measure | CAI | Peer median | Rank |
|---|---|---|---|
| Market value | $8.69B | median $1.00B | 5 of 25 |
| P/E | 82.7× | median 30.6× | 3 of 7 |
| Forward P/E | 225.3× | median 24.6× | 1 of 9 |
| EV/EBITDA | 46.9× | median 24.6× | 2 of 10 |
| P/S | 8.8× | median 2.5× | 9 of 25 |
| FCF yield | 1.6% | median -2.6% | 7 of 25 |
| Operating margin | 15.5% | median -10.4% | 4 of 23 |
| Net margin | 10.6% | median -6.5% | 4 of 23 |
| ROIC | 192.1% | median -15.4% | 1 of 23 |
| ROE | 17.8% | median -8.4% | 3 of 22 |
| Current ratio | 6.2× | median 4.8× | 7 of 25 |
| Stock pay / revenue | 6.6% | median 4.8% | 11 of 24 |
| Share count change | 371.5% | median 3.1% | 2 of 19 |
Green where Caris Life Sciences is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| CAICaris Life Sciences, Inc. | $8.69B | P/E 82.7× | 192.1% | 6.1 |
| NTRANatera, Inc. | $58.00B | P/E – | -31.4% | 4.7 |
| DGXQuest Diagnostics Incorporated | $25.85B | P/E 24.3× | 10.2% | 6.0 |
| LHLaboratory Corporation of America Holdings | $25.78B | P/E 25.7× | 8.2% | 5.6 |
| GHGuardant Health, Inc. | $21.28B | P/E – | -163.9% | 4.2 |
| RDNTRadNet, Inc. | $5.41B | P/E – | 3.2% | 4.1 |
| GRALGRAIL, Inc. | $5.26B | P/E – | -17.8% | 4.1 |
| BLLNBillionToOne, Inc. | $4.18B | P/E 111.0× | 42.9% | 6.1 |
| VCYTVeracyte, Inc. | $3.47B | P/E 30.3× | 8.0% | 7.9 |
| CDNACareDx, Inc. | $3.44B | P/E 31.0× | 164.4% | 7.1 |
| FTREFortrea Holdings Inc. | $2.14B | P/E – | -0.6% | 4.9 |
| PSNLPersonalis, Inc. | $1.69B | P/E – | -351.3% | 3.5 |
| LMRILumexa Imaging Holdings, Inc. | $1.03B | P/E 230.8× | – | 4.0 |
| CSTLCastle Biosciences Inc | $971.78M | P/E – | -11.4% | 5.4 |
| FLGTFulgent Genetics, Inc. | $545.08M | P/E – | -13.0% | 4.3 |
| YDESYD Bio Ltd | $419.07M | P/E – | – | 2.6 |
| BDSXBiodesix Inc | $249.64M | P/E – | -55.9% | 3.9 |
| XGNExagen Inc. | $187.02M | P/E – | -76.2% | 4.7 |
| BNRBurning Rock Biotech Ltd | $142.59M | P/E – | -74.0% | 6.0 |
| SERASera Prognostics, Inc. | $103.98M | P/E – | -227.8% | 3.1 |
| CFORCapForce Inc. | $43.39M | P/E – | 68.9% | 7.2 |
| MDXHMDxHealth SA | $9.94M | P/E – | -25.0% | 5.2 |
| AMSAmerican Shared Hospital Services | $8.51M | P/E – | -5.8% | 4.1 |
| ACONAclarion, Inc. | $5.33M | P/E – | -1069.5% | 3.1 |
| BGLCBioNexus Gene Lab Corp | $3.52M | P/E – | -30.6% | 4.1 |
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.